Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab versus best supportive care for severe COVID-19 pneumonia/acute lung injury/ARDS
jRCT2031200126Phase 3Suspended
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19), pneumonia, acute lung injury (ALI) and 1 more comparing Ravulizumab + best supportive care with Best supportive care (2 arms). Primary endpoint: Survival at Day 29. Started Sep 2020; status: suspended.
02
Drugs
ravulizumab
03
Conditions
coronavirus disease 2019 (COVID-19)pneumoniaacute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on jRCT2031200126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200126.